find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
298
Clinical Trials
Skin and Soft Tissue
Phase II
Accepting Patients
nct/study# NCT04768881 / XPORT-MEL-033
A PHASE 2 OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SELINEXOR IN COMBINATION WITH PEMBROLIZUMAB IN ACTIVELY DIAGNOSED OR RECURRENT ADVANCED MELANOMA
Learn More
Skin and Soft Tissue
Phase II
Accepting Patients
nct/study# NCT04577807 / LUMINOS-102
PVSRIPO with and without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
Learn More
Skin and Soft Tissue
Phase II
Accepting Patients
nct/study# NCT04091750 / IST83
Phase II Study of Nivolumab/Ipilimumab plus Cabozantinib in Patients with Unresectable Advanced Melanoma
Learn More
Skin and Soft Tissue
Phase III
Accepting Patients
nct/study# NCT03712605 / EA6174
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Learn More
Skin and Soft Tissue
Phase II
Accepting Patients
nct/study# NCT04339738 / A091902
A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAÏVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA
Learn More
Thoracic (Lung)
Phase II
Accepting Patients
nct/study# NCT03193437 / 2016-0622
A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.